Combination therapy by using akr1c3-activated compound with immune checkpoint inhibitor
OwnerMing-Tain LAI, Wan-Fen LI +2inventors
InventorsMing-Tain LAI, Wan-Fen LI, Chun-Chung Wang, Lu-Tzu Chen
Life of this patent
Estimating the term…
Abstract
A pharmaceutical composition, including a compound 1-(3-(3-N,N-dimethylaminocarbonyl)phenoxyl-4-mtrophenyl)-1-N ethyl-N,N′-bis(ethylene)phosphoramidate and at least one therapeutic agent including a chemotherapeutic agent or biological agent, and its medical use are provided.
Claims20
A pharmaceutical composition, comprising:
- (1) a compound 1-(3-(3-N,N-dimethylaminocarbonyl)phenoxyl-4-mtrophenyl)-1-ethyl-N,N′-bis(ethylene)phosphoramidate represented by Formula I,
- or a pharmaceutically acceptable salt, isotopic variant or solvate thereof;
- and
- (2) at least one therapeutic agent including a chemotherapeutic agent or biological agent.
A method for inhibiting the growth of cancer cells, comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a compound represented by Formula I-1 or Formula I-2 in combination with an immune checkpoint inhibitor
Dependencies are inferred from the claim text.